Post-traumatic stress disorder

Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting

Retrieved on: 
Friday, December 29, 2023
Biotechnology, Pharmaceutical, Health, Special, Central nervous system, Pain management, Post-traumatic stress disorder, CNS

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barriers, today announced the results of the Special Meeting of Shareholders held on December 28, 2023.

Key Points: 
  • Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barriers, today announced the results of the Special Meeting of Shareholders held on December 28, 2023.
  • The Virpax stockholders approved an amendment to the certificate of incorporation, at the discretion of the Board of Directors of the Company, to effect a reverse stock split.
  • The Company only intends to effect the reverse split to maintain compliance with the $1.00 minimum price bid requirement for continued listing on Nasdaq.
  • The proposals regarding the amendment to the 2022 Equity Incentive Plan and the adjournment of the 2023 Special Meeting to permit further solicitation and vote of proxies did not receive sufficient votes for approval.

An African history of cannabis offers fascinating and heartbreaking insights – an expert explains

Retrieved on: 
Saturday, December 30, 2023
Cannabis, Survivor, Society, Textbook, Ecology, Seed, Research, Smoking, Congo, Income, Human, Plant, Trauma, Anxiety, Post-traumatic stress disorder, Water, Edible, Association, History, Democratic republic, Neocolonialism, Drug

I’ve studied plants from perspectives ranging between ecology and cultural history, including obscure plants and more widely known ones, such as the African baobab.

Key Points: 
  • I’ve studied plants from perspectives ranging between ecology and cultural history, including obscure plants and more widely known ones, such as the African baobab.
  • Cannabis has a truly global history associated with a wide range of uses and meanings.
  • Cannabis has been under global prohibition for most of the last century, which has stunted understanding of the people-plant relationship.
  • Africa, Africans and people of the African diaspora have had crucial roles in the plant’s history that are mostly forgotten.

Medicinal potential

  • The African history of cannabis highlights its medicinal potential, a topic of growing interest.
  • The African past is absent from this medical literature, even though historical observers reported how Africans used cannabis in contexts that justify current interest in its medicinal potential.
  • Their experience justifies exploring cannabis as a potential treatment for post-traumatic stress disorder, anxiety and other conditions.

Exploitative labour

  • Africans have valued cannabis for centuries, though it’s difficult to know all the uses it had, because most weren’t documented.
  • Despite its limits, the historical record clearly shows that people used cannabis as a stimulant and painkiller in association with hard labour.
  • affirm that it wakes them up and warms their bodies, so that they are ready to start up with alacrity.

Africa’s place in global culture

  • I also study cannabis to understand how African knowledge has shaped global culture.
  • Oral histories from Brazil, Jamaica, Liberia and Sierra Leone tell that enslaved central Africans carried cannabis.
  • Around the Atlantic, many terms for cannabis trace to central Africa, including the global word marijuana, derived from Kimbundu mariamba.

Drug policy reforms

  • Drug policy reforms worldwide have opened lucrative, legal markets for cannabis.
  • Most African countries that have enacted drug-policy reforms – notable exceptions being South Africa and Morocco – did so only after foreign businesses paid for cannabis farming licences.
  • These drug-policy reforms don’t meaningfully extend to citizens of African countries.
  • Cannabis-policy reforms in Africa have mostly benefited investors and consumers in wealthy countries, not Africans, a textbook example of neocolonialism.

Way forward

  • In any case, the plant’s African past provides insight into both long-term and emerging issues in humanity’s interactions with cannabis.
  • This is why I study African cannabis.


Chris S. Duvall does not work for, consult, own shares in or receive funding from any company or organisation that would benefit from this article, and has disclosed no relevant affiliations beyond their academic appointment.

Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia

Retrieved on: 
Thursday, December 21, 2023
Psilocybin, Atypical depression, Post-traumatic stress disorder, Treatment, FDA, Ethics, MDMA, PTSD, TGA, Clarion, Authorization, IHL, Patient, Therapeutic Goods Administration, TRD, Environment, Pharmaceutical industry

MELBOURNE, Australia and NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Incannex Healthcare Ltd (Nasdaq: IXHL) (‘Incannex’ or ‘the Company’) a pharmaceutical company developing proprietary medicinal cannabinoid products and psychedelic assisted psychotherapies for unmet needs is pleased to announce that it has received ethics board endorsement for psychedelic assisted therapy at its first clinic based in Melbourne, Australia, a city of approximately 5.2M people.

Key Points: 
  • Incannex subsidiary, Clarion Clinics, has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD.
  • Clarion Clinics is the only dedicated psychedelic-assisted therapy clinic in Australia, with intentions to open more clinics across the country and internationally as legislation permits.
  • Clarion Clinics team includes pre-eminent psychedelic researchers, psychologists and psychiatrists whose expertise can not easily be replicated in Australia.
  • The Melbourne Clarion Clinic will be the first dedicated Psychedelic-assisted therapy clinic in Australia.

Compass Pathways announces investigational COMP360 psilocybin treatment was well-tolerated in phase 2 study of post-traumatic stress disorder

Retrieved on: 
Tuesday, December 19, 2023
Trauma, The Institute, Psilocybin, Lead, Psychiatrist, Mental health, PTSD, Sunstone, Post-traumatic stress disorder, Psychology, Safety, Patient, CMPS, Pharmaceutical industry

This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.

Key Points: 
  • This is believed to be the first study reporting on the feasibility of psilocybin as a potential treatment for PTSD.
  • The open-label study evaluated the safety and tolerability of COMP360 psilocybin treatment in patients with PTSD as a result of trauma experienced as adults.
  • 22 participants received a single 25mg dose of investigational COMP360 psilocybin treatment.
  • It’s encouraging to see these initial safety results for COMP360 psilocybin treatment in this patient population and we look forward to a more detailed analysis of the study next year.”

Sunstone Therapies Celebrates Three Year Anniversary With More Than 100 Psychedelic-Assisted Therapy Treatments Completed

Retrieved on: 
Thursday, December 14, 2023
Veteran, Spectrum, Journal of Affective Disorders, Journal of Psychopharmacology, MAPS, Research, Psychopharmacology, Ketamine, JAMA Oncology, DSM-IV codes, Education, Palliative care, Cancer, University, Sunstone, Post-traumatic stress disorder, Patient, PAT, Journal, Johns Hopkins, Pharmaceutical industry

Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.

Key Points: 
  • Rockville, Maryland, December 14, 2023 – Sunstone Therapies, a leader in the delivery of psychedelic-assisted therapy in the medical setting and the development of clinical trials, announces it has completed more than 100 psychedelic-assisted therapy (PAT) treatments, involving eight different indications, in the three years since the company was founded.
  • Manish Agrawal MD, CEO and Co-founder of Sunstone Therapies, said: “The development of psychedelic-assisted therapy, and the understanding of the impact it can have, has progressed so much over the last three years.
  • We are using the extensive experience we have gained in delivering these therapies, through sponsored clinical trials and our own investigator-initiated studies, to develop a patient-centric delivery model that can be scaled responsibly in the real world.
  • Delivery of psychedelic therapies is complex, requiring significant capabilities and experience in logistics, infrastructure and training, as well as clinical care.

Record-Breaking $700,000 Verdict by Mezrano Law Firm Redefines Justice in Personal Injury Cases

Retrieved on: 
Thursday, November 30, 2023
Injury, Policy, Diagnosis, PTSD, Trauma, Motivation, Post-traumatic stress disorder, Travel, Mental health, Nursing

Birmingham, Alabama, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Mezrano Law Firm, one of the top personal injury law firms in Alabama, has secured a record-breaking $700,000 verdict in Franklin County, eclipsing the previous benchmark of a $550,000 medical malpractice case.

Key Points: 
  • Birmingham, Alabama, Nov. 30, 2023 (GLOBE NEWSWIRE) -- The Mezrano Law Firm, one of the top personal injury law firms in Alabama, has secured a record-breaking $700,000 verdict in Franklin County, eclipsing the previous benchmark of a $550,000 medical malpractice case.
  • Lead counsel Steven Mezrano, alongside fellow Edge lawyers Leah Johnson and Brent Crumpton, spearheaded the trial, setting a new standard for personal injury cases in Franklin County.
  • This accomplishment underscores the Mezrano Law Firm's unwavering commitment to justice and fair compensation for its clients, solidifying its reputation as a legal powerhouse.
  • Established over 15 years ago, the Mezrano Law Firm has consistently demonstrated its dedication to its clients.

America’s VetDogs Provides the Pentagon with Specially Trained Facility Dog

Retrieved on: 
Tuesday, November 28, 2023
Brooke Army Medical Center, Veteran, J-3, Joint Chiefs of Staff, Disability studies, Occupational therapy, Hearing, Disability, Dog, PTSD, Pentagon, Post-traumatic stress disorder, Madigan Army Medical Center, Chief of staff

Smithtown, NY and Washington, DC, Nov. 28, 2023 (GLOBE NEWSWIRE) -- America’s VetDogs is honored to place a specially trained facility dog at the Pentagon with J-3 Operations of the Joint Chiefs of Staff.

Key Points: 
  • Smithtown, NY and Washington, DC, Nov. 28, 2023 (GLOBE NEWSWIRE) -- America’s VetDogs is honored to place a specially trained facility dog at the Pentagon with J-3 Operations of the Joint Chiefs of Staff.
  • Charlie, a 2-year-old yellow Labrador Retriever, was specifically trained as a facility dog to provide animal assisted support for Pentagon personnel and visitors.
  • Charlie becomes the newest valued member of the America's VetDogs facility dog team, joining the ranks of more than 25 facility dogs, including honorary Chief Petty Officer Sully H.W.
  • “We are humbled to have an America’s VetDogs facility dog at the Pentagon to provide support to military and civilian personnel who serve our nation,” said John Miller, president and CEO, America’s VetDogs.

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.

Nema Health, A Virtual PTSD Treatment Program, Raises $4.1M Seed Round And Launches In 3 States

Retrieved on: 
Friday, November 10, 2023
Yale University, Woman, Violence, Medicaid, Post-traumatic stress disorder, Blame, Trauma, Patient, Veteran, Rape, PTSD, Survivor, Medicare, Nightmare, HAVEN, Optum

NEW HAVEN, Conn., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Nema Health (Nema) , a virtual treatment program delivering evidence-based care for post-traumatic stress disorder (PTSD), announced today it has closed a $4.1 million seed round.

Key Points: 
  • NEW HAVEN, Conn., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Nema Health (Nema) , a virtual treatment program delivering evidence-based care for post-traumatic stress disorder (PTSD), announced today it has closed a $4.1 million seed round.
  • The fundraise was co-led by Optum Ventures and .406 Ventures, with participation from GreyMatter Capital and additional angel investors.
  • Nema also announced the launch of its care program in New York, New Jersey and Connecticut with a national insurance partner.
  • The company plans to expand nationwide and to partner with other commercial insurance plans, as well as Medicaid and Medicare.

Battelle Brings Specialized Engineering Capabilities and Clinical Study Expertise to Collaboration with Spark Biomedical on Department of Defense $1.15 Million Grant

Retrieved on: 
Thursday, December 14, 2023
Mental Health, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ASR, Safety, Engineering, Tan, Data science, Post-traumatic stress disorder, Risk, Clinical trial, Acute stress disorder, Partnership, PTSD, Military personnel, Suicide, Medical device

The partnership is part of a $1.15 million Phase II grant awarded to Spark Biomedical, Inc.

Key Points: 
  • The partnership is part of a $1.15 million Phase II grant awarded to Spark Biomedical, Inc.
  • The device, Sparrow® Hawk, uses Transcutaneous Auricular Neurostimulation (tAN®) to prevent or mitigate ASRs in combat settings.
  • In Phase I of the collaboration, Battelle conducted interviews with combat medics to help develop critical benchmarks and performance parameters for a wearable device.
  • “Following this project, we intend to launch a larger clinical trial examining the effects of tAN therapy in those suffering from trauma-induced ASR.”